MELANOMA

This early-stage study tests a new drug called belvarafenib, alone or with other drugs (cobimetinib and nivolumab), in people with advanced melanoma that has a specific NRAS gene change and has stopped responding to standard immunotherapy. The main goals are to check safety and f…

This study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…

This phase 3 trial is testing whether the immunotherapy drug nivolumab (Opdivo) can prevent melanoma from coming back in people who have had their stage IIB/C melanoma completely removed. About 790 adults and children are randomly assigned to receive either nivolumab or a placebo…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This Phase 2 trial tests whether giving a mix of targeted drugs and immunotherapy before and after surgery can reduce the risk of melanoma returning in people with high-risk, resectable tumors. About 95 participants will receive vemurafenib, cobimetinib, and atezolizumab in diffe…

This study tests whether adding hydroxychloroquine (a malaria drug) to standard immunotherapy (nivolumab with or without ipilimumab) can help shrink advanced melanoma tumors. About 41 adults with stage III or IV melanoma that cannot be removed by surgery are participating. The go…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …

This study tests whether adding two experimental vaccines (IO102/IO103) to the standard drug combination of nivolumab and relatlimab can shrink or control advanced melanoma that cannot be removed by surgery. About 43 adults with untreated stage III or IV melanoma will receive the…

This phase 3 trial compares a subcutaneous (under-the-skin) injection of the drug combination nivolumab and relatlimab to the standard intravenous (IV) infusion in people with advanced melanoma that cannot be removed by surgery. The study aims to see if the shot delivers enough d…

This study compares a new biosimilar drug (GME751) to the standard immunotherapy Keytruda in 322 adults with stage II or III melanoma that has been surgically removed. The goal is to see if the biosimilar stays in the body and works as well as Keytruda in preventing the cancer fr…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-phase trial tests a personalized RNA nanoparticle vaccine made from a patient's own tumor. The goal is to help anti-PD-1 immunotherapy work better in people with advanced melanoma or soft tissue sarcoma whose cancer has progressed on standard treatment. Up to 18 partic…

This study tests a new drug called ensartinib in people with advanced melanoma that has a specific genetic abnormality (ALK). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 weeks. Participants must be 18 or older and have already tried …

This study is testing a new combination of two immunotherapy drugs (BGB-A445 and tislelizumab) in about 113 people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the combo can shrink tumors and how safe it is. Participants must have already t…

This early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can…

This early-phase study tests a personalized cell therapy for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, modified to recognize and attack a protein called B…

This study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…

This phase 3 trial tests whether combining two immunotherapy drugs, fianlimab and cemiplimab, works better than the standard drug pembrolizumab for people with advanced melanoma that cannot be surgically removed. About 1,500 adults and adolescents who have not had prior treatment…

This early-phase trial tests a new treatment for people with advanced melanoma that has stopped responding to standard immunotherapy. The treatment uses a patient's own immune cells (TILs) that have been engineered to produce a protein called IL15, combined with a drug called ace…

This phase II trial tests a combination of two immunotherapy drugs, nivolumab and low-dose ipilimumab, given after surgery to patients with stage III or resected stage IV melanoma. The goal is to see if this regimen is safer and more effective than standard high-dose interferon, …

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This phase 2 trial is testing whether giving two immunotherapy drugs, nivolumab and ipilimumab, before surgery can shrink stage III melanoma tumors and prevent the cancer from returning. The 28 participants will also receive an experimental PET scan that images immune cells to se…

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This study tests whether adding two targeted pills (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a BRAF gene mutation. About 257 adults with untreated, advanced or spreading…

This early-stage trial tests a treatment made from a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL). Doctors remove a piece of the tumor, grow the immune cells in a lab, and then infuse them back into the patient to attack the cancer. The study includes 4…

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, in 8 adults with melanoma that stopped responding to PD-1 inhibitors. The goal is to see if the combination can shrink tumors or stop them from growing. The study is active but …

This early-phase trial tests a personalized vaccine called NeoVax, combined with an immune booster (CDX-301) and standard immunotherapy drugs (nivolumab or pembrolizumab), in 10 people with advanced melanoma. The goal is to see if the combination is safe and helps the immune syst…

This early-stage study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have come back or spread and no longer respond to standard treatments. The main goal is to check the drug's safety and find the…

This study tests a treatment that uses a patient's own immune cells (T-cells) to fight advanced melanoma. Some participants also receive a dendritic cell vaccine to boost the immune response. The goal is to see if the T-cells last longer and work better against the cancer. The tr…

This phase 2 trial is testing several combinations of experimental drugs (LXH254, LTT462, trametinib, ribociclib) in 134 people with advanced melanoma that has a BRAF or NRAS mutation and has stopped responding to prior treatment. The main goal is to see if these combinations can…

This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab + nivolumab) can reduce severe immune-related side effects in people with advanced melanoma that cannot be removed by surgery. About 71 participants will receive the three-drug combination during an…

This study tested whether giving the immunotherapy drug pembrolizumab after surgery helps prevent melanoma from returning in people with high-risk stage III melanoma. About 1,000 participants received either pembrolizumab or a placebo for up to a year. The main goal was to see if…

This early-phase trial tests a new three-drug combination for people with advanced BRAF-mutated melanoma that cannot be removed by surgery. The drugs are XL888 (an HSP90 inhibitor), vemurafenib, and cobimetinib. The main goal is to find the safest dose of XL888 when given with th…

This phase II study tests a combination of three drugs—nivolumab, ipilimumab, and cabozantinib—in 14 people with advanced melanoma that cannot be surgically removed. Participants receive the drugs for up to two years. The main goal is to see how long the cancer stays under contro…

This early-phase trial tests whether adding dapansutrile (an anti-inflammatory pill) to pembrolizumab (an immunotherapy) can help people with advanced melanoma whose cancer no longer responds to PD-1 inhibitors. About 26 adults with unresectable stage III or IV melanoma will take…

This study looks at how well and how safely a combination of two cancer drugs, dabrafenib and trametinib, works when given after surgery to Chinese patients with stage III melanoma that has a specific gene change (BRAF V600). The goal is to see if the drugs help delay the cancer'…

This early-phase study tests whether a new treatment called KSQ-001EX is safe for people with advanced solid tumors like melanoma, lung cancer, or head and neck cancer. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are genetically modified …

This study tests whether adding fianlimab to the immunotherapy cemiplimab works better than cemiplimab alone for people with high-risk, removable melanoma. About 151 participants will receive the drugs before surgery, then continue after. The goal is to see if the combination des…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This early-phase study tests a new drug, DKY709, alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and breast cancer. The main goal is to find a safe dose and check for side effects. About 98 adults whose cancer worsened after st…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This phase 3 trial is testing ABP 206, a biosimilar to the immunotherapy drug nivolumab (Opdivo), in 633 people with untreated advanced melanoma. The goal is to see if ABP 206 works just as well as nivolumab in shrinking tumors and extending life, while having a similar safety pr…

This early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …

This study compares two medications, infliximab and vedolizumab, to treat colitis (colon inflammation) caused by immune checkpoint inhibitor therapy in cancer patients. About 47 adults with genitourinary cancer, melanoma, or non-small cell lung cancer are participating. The goal …

This program provides access to the drugs trametinib and dabrafenib for adults with BRAF mutation-positive metastatic melanoma that cannot be surgically removed. Participants take dabrafenib twice daily and trametinib once daily. The goal is to offer treatment to eligible patient…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma tumors that have spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive treatment. The main goal is to see how man…

This phase 2 trial is testing whether adding a personalized mRNA cancer vaccine (mRNA-4157) to the immunotherapy drug pembrolizumab can better prevent melanoma from coming back after surgery compared to pembrolizumab alone. The study involves 267 people with high-risk melanoma th…

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…

This early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…

This early-phase trial tests a new experimental antibody called BI-1607 alongside two existing immunotherapies (ipilimumab and pembrolizumab) in 35 people with advanced melanoma that has spread or cannot be removed. The goal is to see if the combination is safe and can shrink tum…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study …

This study tests whether giving the immunotherapy drug nivolumab before and after surgery for stage III melanoma can help prevent the cancer from returning. About 67 adults with resectable melanoma will receive one dose of nivolumab before surgery, then after surgery they will ge…

This study tests an experimental drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds the safest dose, …

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent melanoma from returning in people with high-risk stage II–IV melanoma. About 1,089 participants who had their melanoma surgically removed will receive e…

This early-stage trial tests whether adding an experimental treatment (MB097) to the immunotherapy drug pembrolizumab is safe and shows signs of working in people with advanced melanoma that did not respond to standard anti-PD1 therapy. About 41 participants will receive the comb…

This early-phase trial tests an experimental drug called AB248, which aims to boost the body's cancer-fighting immune cells. It is given alone or with the approved immunotherapy Keytruda to adults with advanced solid tumors like lung cancer, melanoma, or kidney cancer. The main g…

This study tests whether adding a new immunotherapy drug, relatlimab, to the standard drug nivolumab works better than nivolumab alone for people with advanced melanoma that has spread or cannot be removed by surgery. About 714 participants who have not had prior treatment for th…

This study tests a special camera that uses light and sound to take 3D pictures of skin cancer. The goal is to see how deep and wide a tumor is before surgery. About 200 people with suspected skin cancer will take part. The images will be compared to standard lab results to see i…

This study is testing a blood-based genetic test to find cancer-driving mutations in patients with lung cancer or melanoma. The goal is to see if this simple blood draw can replace the need for a tumor biopsy, which is slower and more invasive. Researchers will check how accurate…

This study looks at whether a blood test that detects tumor DNA can find melanoma recurrence earlier than standard methods. Researchers will follow 467 high-risk patients who have had primary melanoma removed. If the test works, it could lead to faster treatment and better outcom…

This study is testing a gene signature (the Merlin Assay) to see if it can accurately predict whether melanoma has spread to nearby lymph nodes. Researchers are enrolling 1,820 newly diagnosed melanoma patients who are scheduled for a sentinel lymph node biopsy. The goal is to de…

This study tests whether a new imaging technique called multispectral optoacoustic tomography (MSOT) can visualize breast cancer and melanoma tumors. Twelve participants will have MSOT scans before their standard biopsy or treatment. The goal is to see if MSOT can detect tumors a…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say…

This study looks at whether people with melanoma prefer getting their cancer medicine as a shot under the skin or through an IV. About 100 patients will try both ways and say which they like better. The goal is to make treatment more convenient and comfortable for patients.

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This early-phase study tests a new type of proton therapy called Pro-GRID for people with large tumors (over 7 cm) that are hard to treat. The goal is to see if the treatment is safe and can shrink tumors or ease symptoms. About 11 adults with sarcoma or melanoma are taking part.

This study compares proton beam radiation to standard photon radiation (IMRT) for people with head and neck cancer. The goal is to see if proton therapy causes fewer side effects, like painful mouth sores, by exposing less healthy tissue to radiation. About 108 adults with certai…

This study compares two ways of giving high-dose radiation to people whose cancer has spread to bones, spine, soft tissue, or lymph nodes. One schedule gives the radiation in one day, the other over three days. The goal is to see which schedule better controls tumor growth and ha…

This study is not testing a new treatment. Instead, it follows people who already received experimental cell therapies (like growing immune cells from their tumors or blood) in earlier NCI Surgery Branch trials. The goal is to monitor their health for up to 15 years, as required …

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study follows 48 people with advanced melanoma who previously received the experimental drugs fianlimab and cemiplimab in an earlier study. No new treatment is given; instead, researchers track their health, cancer status, and any late side effects over time. The goal is to …

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study is for adults with advanced head and neck, lung, or skin cancer who have not responded to prior treatments. Researchers use special PET scans to see how two experimental drugs (BI 765063 and BI 770371) travel through the body and reach tumors. Participants receive one …

This study is looking at whether a blood test that detects circulating tumor DNA (ctDNA) can help predict if melanoma will come back or spread. Researchers are following 176 adult melanoma patients and comparing ctDNA levels with standard clinical and lab results. The goal is to …

This study tests whether a statewide educational campaign in Oregon helps people spot melanoma earlier. Over 75,000 participants, including patients and healthcare providers, receive training and digital materials. Researchers compare Oregon's results with neighboring states that…

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study looks at whether a high-fiber, plant-based diet and regular exercise can change the gut microbiome in people with melanoma who are receiving immunotherapy. Researchers want to see if these lifestyle changes are feasible and if they might affect how well the treatment w…

This study compares a new total-body PET/CT scanner (uEXPLORER) with a conventional PET/CT scanner in 180 adults with lung cancer, lymphoma, or melanoma. Each participant gets scanned on both machines to see if the new scanner can produce equally good images in a shorter time. Th…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study looks at whether analyzing tumor DNA in the blood can help monitor melanoma after surgery. Researchers will collect blood samples from 136 patients before and after surgery, and every 3-4 months, to see if changes in DNA levels predict when a treatment stops working. T…

This observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future i…

This study collects leftover tissue, blood, and other fluid samples from 6,000 people with benign or malignant tumors of the soft tissue, gastrointestinal tract, or abdomen. Researchers will use these samples in lab studies to better understand the causes, prevention, diagnosis, …

This study looks at how tumors evolve when treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers will take blood samples and tumor biopsies from 14 people with advanced head and neck cancer or melanoma to track genetic changes. The goal is to understand …

This pilot study is testing a radioactive antibody called 124I-Humanized 3F8 to see how it travels through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants will receive the antibody and then have PET/CT scans at several time p…

This study follows 10 children in the Netherlands who received ipilimumab for advanced melanoma that had spread or could not be removed. Researchers are looking at long-term side effects and patient characteristics. The goal is to understand how safe the drug is over time in youn…

This study is testing whether a blood test that looks for tumor DNA can help doctors decide when to safely stop immunotherapy in people with advanced melanoma or non-small cell lung cancer. About 39 patients who have been on immunotherapy for at least a year and show no signs of …